Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Accumulated Expenses (2016 - 2025)

Dare Bioscience (DARE) has disclosed Accumulated Expenses for 11 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses rose 25.61% year-over-year to $2.3 million, compared with a TTM value of $2.3 million through Sep 2025, up 25.61%, and an annual FY2024 reading of $3.0 million, up 5.33% over the prior year.
  • Accumulated Expenses was $2.3 million for Q3 2025 at Dare Bioscience, down from $2.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $10.9 million in Q4 2022 and bottomed at $250000.0 in Q2 2021.
  • Average Accumulated Expenses over 5 years is $3.5 million, with a median of $3.0 million recorded in 2024.
  • The sharpest move saw Accumulated Expenses tumbled 84.76% in 2021, then soared 2438.95% in 2022.
  • Year by year, Accumulated Expenses stood at $3.1 million in 2021, then soared by 247.36% to $10.9 million in 2022, then tumbled by 73.48% to $2.9 million in 2023, then grew by 5.33% to $3.0 million in 2024, then dropped by 23.6% to $2.3 million in 2025.
  • Business Quant data shows Accumulated Expenses for DARE at $2.3 million in Q3 2025, $2.5 million in Q2 2025, and $1.8 million in Q1 2025.